fabomotizole
Fabomotizole is an anxiolytic drug launched in Russia in the early 2000s. It produces anxiolytic and neuroprotective effects without any sedative or muscle relaxant actions. Its mechanism of action remains poorly defined however, with GABAergic, NGF- and BDNF-release-promoting, MT1 receptor agonism, MT3 receptor antagonism, and sigma agonism suggested as potential mechanisms. Fabomotizole was shown to inhibit MAO-A reversibly and there might be also some involvement with serotonin receptors. Clinical trials have shown fabomotizole to be well tolerated and reasonably effective for the treatment of anxiety. — Wikipedia
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Earliest trial started Oct 2, 2018 (NCT04524975)
Timeline
Indications
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
SMILES
CCOc1ccc2nc(SCCN3CCOCC3)[nH]c2c1- Mol. weight
- 307.42 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaFabomotizole ↗
- ChEMBLCHEMBL3707307 ↗
Also known as
- afobazol
- afobazol
- afobazol
- afobazol
- afobazole
- aphobazole
- fabomotizole
- fabomotizole
- fabomotizole
- fabomotizole
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06843044 | Phase 4 | Jan 13, 2025 | Valenta Pharm JSC |
| NCT04598867 | Phase 3 | Dec 31, 2020 | ChemRar Research and Development Institute, LLC |
| NCT04524975 | Phase 2 | Oct 2, 2018 | ChemRar Research and Development Institute, LLC |
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ChemRar Research and Development Institute, LLC | Academic/Hospital | 2 | 2 | 2 | 2018 |
| Valenta Pharm JSC | For profit | 1 | 1 | 1 | 2025 |